Literature DB >> 14975714

Essential roles of Meltrin beta (ADAM19) in heart development.

Kazuto Kurohara1, Kouji Komatsu, Tomohiro Kurisaki, Aki Masuda, Naoki Irie, Masahide Asano, Katsuko Sudo, Yo-ichi Nabeshima, Yoichiro Iwakura, Atsuko Sehara-Fujisawa.   

Abstract

Morphogenesis of the heart requires development of the endocardial cushion tissue that gives rise to the membranous septa and valves. Here we show that Meltrin beta/ADAM19, a novel metalloprotease-disintegrin, participates in the development of the endocardial cushion. Mice lacking Meltrin beta exhibit ventricular septal defect (VSD) and immature valves, and most of the animals die soon after birth. During development of the endocardial cushion, epithelial-mesenchymal transformation (EMT) of endocardial epithelial cells generates most of the cushion mesenchymes that constitute the main components of the septa and valves. Meltrin beta is expressed in both the epithelia and the mesenchymes of the endocardial cushion. In the absence of Meltrin beta, the cushion is small or thin in the septum-forming region and show poor remodeling of cardiac jelly components; both of these characteristics suggest impaired growth and differentiation of the endocardial cushion. When embryonic fibroblasts are cultured sparsely, Meltrin beta-lacking cells exhibit aberrant ectodomain shedding of type I Neuregulin, one of the ErbB ligands expressed in endocardial cells. These results suggest the necessity of proteolytic regulation of ErbB ligands by Meltrin beta for proper heart development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14975714     DOI: 10.1016/j.ydbio.2003.10.021

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  26 in total

1.  Metalloproteinase processing of HBEGF is a proximal event in the response of human aortic endothelial cells to oxidized phospholipids.

Authors:  Sangderk Lee; James R Springstead; Brian W Parks; Casey E Romanoski; Roland Palvolgyi; Tiffany Ho; Phuc Nguyen; Aldons J Lusis; Judith A Berliner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-08       Impact factor: 8.311

2.  ADAM33 is not essential for growth and development and does not modulate allergic asthma in mice.

Authors:  Chun Chen; Xiaozhu Huang; Dean Sheppard
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

3.  Microdeletions and microduplications in patients with congenital heart disease and multiple congenital anomalies.

Authors:  Elizabeth Goldmuntz; Prasuna Paluru; Joseph Glessner; Hakon Hakonarson; Jaclyn A Biegel; Peter S White; Xiaowu Gai; Tamim H Shaikh
Journal:  Congenit Heart Dis       Date:  2011-10-20       Impact factor: 2.007

Review 4.  The role of Neuregulin-1beta/ErbB signaling in the heart.

Authors:  Laura Pentassuglia; Douglas B Sawyer
Journal:  Exp Cell Res       Date:  2008-09-03       Impact factor: 3.905

5.  Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells.

Authors:  April Kalinowski; Nicola J R Plowes; Qunhua Huang; Carla Berdejo-Izquierdo; Raymond R Russell; Kerry S Russell
Journal:  FASEB J       Date:  2010-03-09       Impact factor: 5.191

Review 6.  A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease.

Authors:  Sheng Zhong; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2019-03-21       Impact factor: 5.858

7.  Endothelial deletion of ADAM17 in mice results in defective remodeling of the semilunar valves and cardiac dysfunction in adults.

Authors:  Carole L Wilson; Peter J Gough; Cindy A Chang; Christina K Chan; Jeremy M Frey; Yonggang Liu; Kathleen R Braun; Michael T Chin; Thomas N Wight; Elaine W Raines
Journal:  Mech Dev       Date:  2013-01-24       Impact factor: 1.882

Review 8.  ADAM function in embryogenesis.

Authors:  Dominique Alfandari; Catherine McCusker; Hélène Cousin
Journal:  Semin Cell Dev Biol       Date:  2008-09-30       Impact factor: 7.727

9.  Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?

Authors:  Xiang Wang; Ana-Maria Bosonea; Jeffrey Odenbach; Carlos Fernandez-Patron
Journal:  Curr Hypertens Rev       Date:  2012-08-01

10.  Proteomic-based detection of a protein cluster dysregulated during cardiovascular development identifies biomarkers of congenital heart defects.

Authors:  Anjali K Nath; Michael Krauthammer; Puyao Li; Eugene Davidov; Lucas C Butler; Joshua Copel; Mikko Katajamaa; Matej Oresic; Irina Buhimschi; Catalin Buhimschi; Michael Snyder; Joseph A Madri
Journal:  PLoS One       Date:  2009-01-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.